{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-005477","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.527635+00:00","generated_at":"2026-05-26T01:28:10.315861+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Puma Biotechnology reports Q4 GAAP net income $19.3M ($0.39 EPS); guides FY2025 net income $23-28M","bullets":["Q4 product revenue net $54.4M (up from $53.2M YoY); full year $195.2M (down from $203.1M).","GAAP net income $30.3M ($0.62/share) for FY2024 vs. $21.6M ($0.46) in FY2023.","Non-GAAP adjusted net income $38.5M ($0.79/share) for FY2024 vs. $31.8M ($0.68) in FY2023.","Cash and securities $101M at Dec 31, 2024; operating cash flow $38.9M for FY2024.","FY2025 guidance: net product revenue $192-198M; net income $23-28M (excludes valuation allowance)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-005477","json":"https://secwatch.observer/filing/0001437749-25-005477.json","markdown":"https://secwatch.observer/filing/0001437749-25-005477.md","text":"https://secwatch.observer/filing/0001437749-25-005477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774925005477/0001437749-25-005477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774925005477/pbyi20250224_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:28:10.315861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}